[go: up one dir, main page]

NO20013442D0 - Sammensetninger som oppnår en forbedret levering av aktive stoffer - Google Patents

Sammensetninger som oppnår en forbedret levering av aktive stoffer

Info

Publication number
NO20013442D0
NO20013442D0 NO20013442A NO20013442A NO20013442D0 NO 20013442 D0 NO20013442 D0 NO 20013442D0 NO 20013442 A NO20013442 A NO 20013442A NO 20013442 A NO20013442 A NO 20013442A NO 20013442 D0 NO20013442 D0 NO 20013442D0
Authority
NO
Norway
Prior art keywords
compositions
achieve
active substances
improved delivery
delivery
Prior art date
Application number
NO20013442A
Other languages
English (en)
Other versions
NO20013442L (no
Inventor
Douglas Joseph Dobrozsi
Ii Jerry William Hayes
Kishorkumar Jivanlal Desai
Brian James Robbins
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20013442D0 publication Critical patent/NO20013442D0/no
Publication of NO20013442L publication Critical patent/NO20013442L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20013442A 1999-01-11 2001-07-11 Sammensetninger som oppnar en forbedret levering av aktive stoffer NO20013442L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11537899P 1999-01-11 1999-01-11
PCT/US2000/000575 WO2000041693A2 (en) 1999-01-11 2000-01-10 Compositions having improved delivery of actives

Publications (2)

Publication Number Publication Date
NO20013442D0 true NO20013442D0 (no) 2001-07-11
NO20013442L NO20013442L (no) 2001-09-11

Family

ID=22361013

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013442A NO20013442L (no) 1999-01-11 2001-07-11 Sammensetninger som oppnar en forbedret levering av aktive stoffer

Country Status (15)

Country Link
US (1) US6846495B2 (no)
EP (1) EP1140093A2 (no)
JP (1) JP2002534463A (no)
KR (1) KR100511730B1 (no)
CN (1) CN1203854C (no)
AU (1) AU762366B2 (no)
BR (1) BR0007445A (no)
CA (1) CA2356881C (no)
CO (1) CO5270007A1 (no)
CZ (1) CZ20012491A3 (no)
HU (1) HUP0105021A3 (no)
NO (1) NO20013442L (no)
PE (1) PE20001415A1 (no)
TR (1) TR200101927T2 (no)
WO (1) WO2000041693A2 (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228237B1 (en) 2000-03-09 2013-02-28 Gw Pharma Ltd Pharmaceutical compositions comprising cannabis and a pump spray device for the delivery of the compositions
CN1215837C (zh) * 2000-08-25 2005-08-24 兴和株式会社 布洛芬胶囊填充液和胶囊制剂
US7138133B2 (en) * 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
BRPI0517891A (pt) 2004-11-24 2008-10-21 Medpointe Healthcare Inc composições compreendendo azelastina e métodos de uso das mesmas
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
PL1848419T3 (pl) * 2005-02-01 2012-12-31 Troikaa Pharmaceuticals Ltd Preparaty diklofenaku i jego farmaceutycznie dopuszczalnych soli do wstrzykiwań
PL2001452T3 (pl) 2006-04-05 2017-02-28 Intercontinental Great Brands Llc Kompleks fosforanu wapnia w gumie do żucia zawierającej kwas
CA2648460C (en) 2006-04-05 2014-09-23 Cadbury Adams Usa Llc Calcium phosphate complex and salts in oral delivery systems
AU2007264968B2 (en) * 2006-06-29 2011-05-26 Intercontinental Great Brands Llc Improved chain cutter for continuously forming center-filled gum pieces
PL2187758T5 (pl) * 2007-07-27 2022-01-31 Intercontinental Great Brands Llc Sposób i urządzenie do przetwarzania wyrobów cukierniczych
DE102007000521A1 (de) * 2007-10-18 2009-04-23 Renate Conrad Hustenpräparat
ES2393224T5 (es) † 2008-02-08 2020-09-14 Procter & Gamble Proceso para fabricar una bolsa soluble en agua
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
EP2852571A4 (en) 2012-05-23 2015-11-25 Cellix Bio Private Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF MUCOSITIS
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
CN104603100A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗炎症性肠病的组合物和方法
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
GB201215988D0 (en) * 2012-09-07 2012-10-24 Reckitt Benckiser Healthcare Int Ltd Pharmaceutical compositions comprising flurbiprofen
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
SG11201702554QA (en) 2014-09-29 2017-04-27 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP3229820A4 (en) * 2014-12-12 2018-07-11 Ari Healthcare Pvt. Ltd. A mouth freshener
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN107428697A (zh) 2015-01-06 2017-12-01 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
US11234897B2 (en) * 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
WO2019222100A1 (en) 2018-05-16 2019-11-21 Zumeta Perez Javier High concentration suspension formulation for cold and flu soft gel capsule medications

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3085942A (en) * 1960-12-28 1963-04-16 Hoffmann La Roche Antitussive compositions and preparation
US4136163A (en) 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
CA1027347A (en) 1972-07-20 1978-03-07 David G. Rowsell Compounds having a physiological cooling effect and compositions containing them
SE7812207L (sv) 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
US4474985A (en) 1981-07-06 1984-10-02 Monsanto Company Purification of N-acetyl aminophenols
JPS5888334A (ja) 1981-11-20 1983-05-26 Takasago Corp ３−ｌ−メントキシプロパン−１、２−ジオ−ル
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
GB8629567D0 (en) 1986-12-10 1987-01-21 Boots Co Plc Therapeutic agents
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US4883660A (en) * 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5196486A (en) 1989-03-17 1993-03-23 Nalco Chemical Company Alkoxylated vinyl polymer demulsifiers
US5100898A (en) 1990-01-25 1992-03-31 Richardson-Vicks Inc. Antitussive liquid compositions containing dyclonine
US5196436A (en) 1990-10-31 1993-03-23 The Procter & Gamble Company Dextromethorphan antitussive compositions
PL168968B1 (en) * 1990-10-31 1996-05-31 Procter & Gamble Method of manufacturing an antitussive drug
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
AU6086794A (en) 1993-02-18 1994-09-14 Warner-Lambert Company Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents
US5505961A (en) 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
CA2181241C (en) 1994-01-24 2000-04-25 Dadi Jamshed Dhabhar Process for solubilizing difficultly soluble pharmaceutical actives
US5510389A (en) 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5846557A (en) * 1996-03-20 1998-12-08 Cumberland Packing Corporation Chewing gum containing cough suppressing agent
US5955098A (en) 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
EP0910339B1 (en) * 1996-04-12 2005-02-02 Novadel Pharma Inc. Buccal polar spray
SE9601528D0 (sv) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
AU7916798A (en) 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
JP2001517689A (ja) 1997-10-01 2001-10-09 フレミントン ファーマシューティカル コーポレイション 極性または非極性の、バッカルスプレーまたはカプセル

Also Published As

Publication number Publication date
CN1336823A (zh) 2002-02-20
US6846495B2 (en) 2005-01-25
EP1140093A2 (en) 2001-10-10
CO5270007A1 (es) 2003-04-30
NO20013442L (no) 2001-09-11
AU2962700A (en) 2000-08-01
CZ20012491A3 (cs) 2001-12-12
PE20001415A1 (es) 2001-01-05
TR200101927T2 (tr) 2001-11-21
US20030139437A1 (en) 2003-07-24
CN1203854C (zh) 2005-06-01
WO2000041693A3 (en) 2000-11-30
BR0007445A (pt) 2001-10-16
CA2356881A1 (en) 2000-07-20
JP2002534463A (ja) 2002-10-15
HUP0105021A2 (hu) 2002-05-29
HUP0105021A3 (en) 2003-02-28
KR100511730B1 (ko) 2005-08-31
WO2000041693A2 (en) 2000-07-20
CA2356881C (en) 2012-02-28
AU762366B2 (en) 2003-06-26
KR20010093255A (ko) 2001-10-27

Similar Documents

Publication Publication Date Title
NO20013442D0 (no) Sammensetninger som oppnår en forbedret levering av aktive stoffer
FR2795324B1 (fr) Compositions pharmaceutiques stabilisees
NO20035654D0 (no) System for avlevering av törrpulverformuleringer
DK0753506T3 (da) 6-Dimethylaminomethyl-1-phenyl-cyclohexanforbindelser som farmaceutisk aktive stoffer
DK0780369T3 (da) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-forbindelser som farmaceutisk virksomme stoffer
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
EP1461044A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE COMPOUNDS OF VITAMIN D
NO20013742L (no) Spiselige beleggblandinger
DZ3170A1 (fr) Livraison de produits pharmaceutiques instables.
WO2002051424A8 (fr) Medicaments contre les defaillances articulaires
EE04450B1 (et) Farmatseutilised kompositsioonid kahe või enama toimeainega aerosoolidele
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
ATE263558T1 (de) Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
AU2002302814A1 (en) Spray freeze-dried compositions
AU6103200A (en) Perfume compositions
ZA200109236B (en) Pharmaceutical compositions of erythropoietin.
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
HUP0203311A3 (en) New pharmaceutical compositions of prolonged effect
IL150905A0 (en) Andrographolide derivatives and pharmaceutical compositions containing the same
PT1239832E (pt) Composicoes farmaceuticas
DK1083790T3 (da) Retardformuleringer af aktive stoffer til plantebeskyttelse
HUP0203275A3 (en) 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants
DK1106174T3 (da) Sammensætninger der indeholder fedtoplöselige vitaminer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application